Literature DB >> 21213204

Management of the patient with a malignant pleural effusion.

John E Heffner1.   

Abstract

A malignant pleural effusion (MPE) establishes an incurable stage of a malignancy. Median survival after detection of an MPE is 4 to 6 months in general populations of patients with cancer. Management of MPE centers on palliation of symptoms because no available treatments prolong survival. Mismanagement of MPE, however, can shorten survival and add to patients' burden of disease. Appropriate management requires a multidisciplinary approach with competency in existing treatment modalities to allow individualization of care. Although few prospective studies exist to guide clinical decisions, treating centers should present to patients the relative risks and benefits of different approaches and ensure that their institution's clinical outcomes in managing MPE match those of best clinical practices reported in the literature. Treatment of MPE is moving toward less interventional approaches that can manage patients in ambulatory settings thereby decreasing cost, discomfort, and time away from home for inpatient care. © Thieme Medical Publishers.

Entities:  

Mesh:

Year:  2011        PMID: 21213204     DOI: 10.1055/s-0030-1269831

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  10 in total

1.  Malignant pleural effusion: further translational research is crucial.

Authors:  Yasuhiko Nishioka
Journal:  Transl Lung Cancer Res       Date:  2012-09

2.  High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.

Authors:  Yin Tang; Zhuo Wang; Ziming Li; Jungwoo Kim; Yuliang Deng; Yan Li; James R Heath; Wei Wei; Shun Lu; Qihui Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

3.  Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice.

Authors:  Yunfen Wang; Yanwen Yao; Hongbin Liu; Xingqun Ma; Tangfeng Lv; Dongmei Yuan; Xinwu Xiao; Jie Yin; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-02

Review 4.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

5.  Treatment of malignant pleural effusion: a cost-effectiveness analysis.

Authors:  Varun Puri; Tanya L Pyrdeck; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; Graham A Colditz; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2012-05-10       Impact factor: 4.330

6.  Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Qiang Wu; Min Li; Shu Zhang; Lu Chen; Xingting Gu; Feng Xu
Journal:  Exp Ther Med       Date:  2014-10-30       Impact factor: 2.447

7.  Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion.

Authors:  Klaus Hackner; Peter Errhalt; Sabin Handzhiev
Journal:  Ther Adv Med Oncol       Date:  2019-05-22       Impact factor: 8.168

8.  Retrospective case-control study on the outcomes of early minimally invasive pleural lavage for pleural empyema in oncology patients.

Authors:  Paolo Nicola Camillo Girotti; Peter Tschann; Paolo Di Stefano; Martin Möschel; Nikolaus Hübl; Ingmar Königsrainer
Journal:  Thorac Cancer       Date:  2021-08-17       Impact factor: 3.500

9.  Superiority and clinical significance of Lunx mRNA in the diagnosis of malignant pleural effusion caused by pulmonary carcinoma.

Authors:  Ying Tang; Lijun Xu
Journal:  J Exp Clin Cancer Res       Date:  2013-06-08

10.  Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization.

Authors:  Annalisa Bosi; Silvia Zanellato; Barbara Bassani; Adriana Albini; Alessandra Musco; Maria Cattoni; Matteo Desio; Elisa Nardecchia; Davide Giuseppe D'Urso; Andrea Imperatori; Lorenzo Dominioni; Douglas M Noonan; Lorenzo Mortara; Antonino Bruno
Journal:  J Immunol Res       Date:  2018-03-29       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.